Week In Review: CStone Acquires China Rights To Leukemia Drug In $424 Million Deal

CStone Pharma of Suzhou acquired rights to a novel cancer drug from Agios in a deal worth up to $424 million. CStone will have rights to ivosidenib in greater China. It will initially target acute myeloid leukemia (AML) and cholangiocarcinoma.